The Ras superfamily of GTPases has 167 proteins that are involved in various cellular processes such as proliferation, transformation, migration, and inhibition of cell death. Mutations, abnormal expression, and function of these proteins are observed in many diseases, including several forms of cancer. Even though these GTPases were among the first discovered oncogenes, no successful Ras drug candidate has successfully passed clinical trials. Drugs targeting these proteins have failed mainly because of the complexity of their regulation, their high affinity to GTP, and their structure’s dynamic nature. Recently, novel promising targeting approaches have renewed interest in the Ras drug discovery field. One such approach uses small molecule...
<div><p>Overactive GTPases have often been linked to human diseases. The available inhibitors are li...
The RAS gene family is frequently mutated in human cancers, and the quest for compounds that bind to...
AbstractThree decades after identification of the Ras oncogene, no effective treatments for Ras muta...
The Ras superfamily of small G proteins are involved in cell-signaling processes that, if not regula...
Aberrant Ras signalling drives 30% of cancers and inhibition of Rho family small-GTPase signalling h...
Abnormal functioning of small GTPases is implicated in a variety of diseases, ranging from neurologi...
Overactive GTPases have often been linked to human diseases. The available inhibitors are limited an...
Cdc42 plays important roles in cytoskeleton organization, cell cycle progression, signal transductio...
Low molecular weight guanine triphosphate hydrolases (GTPases) are GTP-binding enzymes that play piv...
Despite more than three decades of intense effort, no anti-Ras therapies have reached clinical appli...
Somatic mutations in the small GTPase K-Ras are the most common activating lesions found in human ca...
The Ras superfamily of small GTPases are guanine nucleotide dependent switches essential for numerou...
Prior work has indicated that preventing Cdc42 interacting with its downstream effector proteins can...
Eukaryotic cells contain an extensive amount of GTP/GDP binding proteins. Proteins known as Ras GTPa...
Ras oncoproteins play a crucial role in the onset, maintenance, and progression of the most common a...
<div><p>Overactive GTPases have often been linked to human diseases. The available inhibitors are li...
The RAS gene family is frequently mutated in human cancers, and the quest for compounds that bind to...
AbstractThree decades after identification of the Ras oncogene, no effective treatments for Ras muta...
The Ras superfamily of small G proteins are involved in cell-signaling processes that, if not regula...
Aberrant Ras signalling drives 30% of cancers and inhibition of Rho family small-GTPase signalling h...
Abnormal functioning of small GTPases is implicated in a variety of diseases, ranging from neurologi...
Overactive GTPases have often been linked to human diseases. The available inhibitors are limited an...
Cdc42 plays important roles in cytoskeleton organization, cell cycle progression, signal transductio...
Low molecular weight guanine triphosphate hydrolases (GTPases) are GTP-binding enzymes that play piv...
Despite more than three decades of intense effort, no anti-Ras therapies have reached clinical appli...
Somatic mutations in the small GTPase K-Ras are the most common activating lesions found in human ca...
The Ras superfamily of small GTPases are guanine nucleotide dependent switches essential for numerou...
Prior work has indicated that preventing Cdc42 interacting with its downstream effector proteins can...
Eukaryotic cells contain an extensive amount of GTP/GDP binding proteins. Proteins known as Ras GTPa...
Ras oncoproteins play a crucial role in the onset, maintenance, and progression of the most common a...
<div><p>Overactive GTPases have often been linked to human diseases. The available inhibitors are li...
The RAS gene family is frequently mutated in human cancers, and the quest for compounds that bind to...
AbstractThree decades after identification of the Ras oncogene, no effective treatments for Ras muta...